tiprankstipranks
Trending News
More News >
Buy Rating for Unicycive Therapeutics Driven by Strategic Positioning and Upcoming Regulatory Milestones
PremiumRatingsBuy Rating for Unicycive Therapeutics Driven by Strategic Positioning and Upcoming Regulatory Milestones
23d ago
Unicycive Therapeutics reports Q1 EPS (5c), consensus (6c)
Premium
The Fly
Unicycive Therapeutics reports Q1 EPS (5c), consensus (6c)
26d ago
Unicycive Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Unicycive Therapeutics initiated with a Buy at Guggenheim
2M ago
Promising Prospects for Unicycive Therapeutics: Buy Rating Backed by Upcoming Milestones and Strategic Preparations
PremiumRatingsPromising Prospects for Unicycive Therapeutics: Buy Rating Backed by Upcoming Milestones and Strategic Preparations
2M ago
Unicycive Therapeutics price target raised to $7.50 from $4 at H.C. Wainwright
Premium
The Fly
Unicycive Therapeutics price target raised to $7.50 from $4 at H.C. Wainwright
2M ago
Unicycive Therapeutics reports FY24 EPS (56c), consensus (51c)
Premium
The Fly
Unicycive Therapeutics reports FY24 EPS (56c), consensus (51c)
2M ago
Unicycive Therapeutics announces publication of OLC dose escalation data
PremiumThe FlyUnicycive Therapeutics announces publication of OLC dose escalation data
5M ago
Unicycive announces puvlication of OLC positive bioequivalence data
Premium
The Fly
Unicycive announces puvlication of OLC positive bioequivalence data
6M ago
Unicycive Therapeutics price target raised to $4 from $2.50 at H.C. Wainwright
Premium
The Fly
Unicycive Therapeutics price target raised to $4 from $2.50 at H.C. Wainwright
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100